xefo rapid
actiofarma, uab - lornoksikamas - plėvele dengtos tabletės - 8 mg - lornoxicam
ticagrelor mylan
viatris limited - tikagreloras - plėvele dengtos tabletės - 90 mg - ticagrelor
ticagrelor zentiva
zentiva k.s. - tikagreloras - plėvele dengtos tabletės - 90 mg - ticagrelor
plategra
egis pharmaceuticals plc - tikagreloras - plėvele dengtos tabletės - 60 mg - ticagrelor
plategra
egis pharmaceuticals plc - tikagreloras - plėvele dengtos tabletės - 90 mg - ticagrelor
ketoprofen rompharm
adeofarma, uab - ketoprofenas - injekcinis ar infuzinis tirpalas - 100 mg/2 ml - ketoprofen
ertapenem sun
sun pharmaceutical industries (europe) b.v. - ertapenemo natrio druska - bakterinė infekcija - ertapenem - treatmentertapenem sun is indicated in paediatric patients (3 months to 17 years of age) and in adults for the treatment of the following infections when caused by bacteria known or very likely to be susceptible to ertapenem and when parenteral therapy is required (see sections 4. 4 ir 5. 1):- intra-abdominal infections- community acquired pneumonia- acute gynaecological infections- diabetic foot infections of the skin and soft tissue (see section 4. 4)preventionertapenem sun is indicated in adults for the prophylaxis of surgical site infection following elective colorectal surgery (see section 4. reikėtų atsižvelgti į oficialius nurodymus, kaip tinkamai naudoti antibakterinių veiksnių.
spevigo
boehringer ingelheim international gmbh - spesolimab - psoriazė - imunosupresantai - spevigo is indicated for the treatment of flares in adult patients with generalised pustular psoriasis (gpp) as monotherapy.
imjudo
astrazeneca ab - tremelimumab - carcinoma, hepatocellular - antinavikiniai vaistai - imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc). imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.